PFE

Pfizer, Inc.

53.91
USD
-0.15%
53.91
USD
-0.15%
38.48 61.71
52 weeks
52 weeks

Mkt Cap 300.72B

Shares Out 5.58B

Chat
Send me real-time posts from this site at my email

Why Coronavirus Vaccine Stocks Topped the Market Today

What happened Shares of coronavirus vaccine makers generally had a good Wednesday on the back of a coming push on additional jabs, plus a notable recommendation boost by a prominent investment bank. In contrast to the day's dip in the S&P 500 index, Moderna (NASDAQ: MRNA) stock enjoyed a 1.6% lift, Comirnaty vaccine co-developers Pfizer (NYSE: PFE) and BioNTech (NASDAQ: BNTX) respectively rose by 0.9% and 2.7%, and perennial underdog Novavax (NASDAQ: NVAX) gained 2.6%. So what Various media reports published Wednesday indicate that the U.S. Centers for Disease Control and Prevention (CDC) will push American pharmacies to cease refusing fourth coronavirus vaccine shots for immuno-compromised people. The CDC will apparently make its request in a scheduled conference call later this week with pharmacy leaders. This follows numerous reports throughout the country of patients being turned away for jab No. 4. The reluctance is somewhat puzzling as the CDC issued guidance last October that such patients should receive the extra primary shot. Any initiative to get more shots in arms is particularly a boon for the vaccines that have been either approved or authorized in the U.S. The two leaders in this small category are the Pfizer/BioNTech jab and Moderna's mRNA-1273. Novavax is not on that list, but earlier this month the biotech filed its clinical trial data with the Food and Drug Administration (FDA). This is a key step in applying for the regulator's Emergency Use Authorization (EUA). So authorization for the company's NVX-CoV2373 might be coming soon. Now what At the moment, Moderna, BioNTech, and -- to a lesser extent -- Novavax stocks are more prone to swings in the fortunes of vaccines. This is because all are still heavily dependent on jabs for their business in contrast to large and diversified healthcare juggernaut Pfizer. That helps explain why a positive analyst note on Moderna is giving that stock a particular lift. On Wednesday, Deutsche Bank analyst Emmanuel Papadakis upgraded his recommendation on the stock to hold from the former sell (although he cut his price target to $175 per share from $200). 10 stocks we like better than Moderna Inc. When our award-winning analyst team has a stock tip, it can pay to listen. After all, the newsletter they have run for over a decade, Motley Fool Stock Advisor, has tripled the market.* They just revealed what they believe are the ten best stocks for investors to buy right now... and Moderna Inc. wasn't one of them! That's right -- they think these 10 stocks are even better buys. *Stock Advisor returns as of January 10, 2022 Eric Volkman has no position in any of the stocks mentioned. The Motley Fool recommends Moderna Inc. The Motley Fool has a disclosure policy. The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc. Founded in 1993 in Alexandria, VA., by brothers David and Tom Gardner, The Motley Fool is a multimedia financial-services company dedicated to building the world's greatest investment community. Reaching millions of people each month through its website, books, newspaper column, radio show, television appearances, and subscription newsletter services, The Motley Fool champions shareholder values and advocates tirelessly for the individual investor. The company's name was taken from Shakespeare, whose wise fools both instructed and amused, and could speak the truth to the king -- without getting their heads lopped off.

Welcome! Is it your First time here?

What are you looking for? Select your points of interest to improve your first-time experience:

Apply & Continue